BiotechTube
Agrisera

Agrisera

Vännäs, Sweden· Est.
agrisera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Agrisera is a privately held, revenue-generating Swedish antibody producer serving the global life science research market. Founded in 2001, the company has established a strong niche in plant and algal research antibodies while expanding into adjacent areas like human cell biology and coronavirus research. Its business model is based on manufacturing and selling primary and secondary antibodies, detection reagents, and related research tools directly to academic and industrial laboratories. The company leverages its expertise to provide specialized products and technical support to a dedicated customer base.

Antibodies

Technology Platform

Polyclonal and monoclonal antibody production and conjugation platform, with specialization in antibodies for plant and algal research and broad species cross-reactivity.

Opportunities

Growing global focus on plant science for food security and climate change supports demand for specialized research tools.
The trend towards antibody validation and reproducibility favors established, quality-focused providers like Agrisera.
Expansion into adjacent areas like human cell biology and virology allows for market diversification.

Risk Factors

Reliance on the niche plant research market, which is smaller and subject to funding fluctuations.
Intense competition from large, diversified life science reagent companies.
Risks associated with biological manufacturing supply chains and potential technological disruption in protein detection methods.

Competitive Landscape

Agrisera competes in a fragmented but competitive global antibody market. It holds a strong position in the specialized plant and algal research niche, competing with a few other specialists and the plant biology portfolios of large players like Thermo Fisher Scientific. In human cell biology and secondary antibodies, it faces intense competition from giants like Abcam, Cell Signaling Technology, Santa Cruz Biotechnology, and Merck Millipore.

More companies in Biologics / Biosimilars →More companies in Sweden →